Mevion Medical Systems Continues Manufacturing Ramp up for its Revolutionary MEVION S250 Proton Ther
Mevion Medical Systems Continues Manufacturing Ramp up for its Revolutionary MEVION S250 Proton Therapy System
A Fifth Proton Accelerator Enters Manufacturing Line at Mevion Headquarters
LITTLETON, Mass.--(BUSINESS WIRE)-- Today, Mevion Medical Systems announces the delivery of its fifth TriNiobium Core proton accelerator, the powerful proton source that is at the center of the revolutionary MEVION S250 Proton Therapy System. This accelerator will be delivered early next year to First Coast Oncology in Jacksonville, Florida, a leading physician owned radiation oncology center. All 2013 and early 2014 MEVION S250 deliveries are already in the manufacturing stage.
"The MEVION S250 has redefined the economics, availability, and the future direction of proton therapy, by bringing the management and operation of proton therapy to the level of modern radiation therapy", says Dr. Scot Ackerman, Medical Director for First Coast Oncology. "Our Mission has been to provide the most advanced radiation treatment for our cancer patients, and the MEVION S250 will allow us to offer to our patients the full benefits of proton therapy".
The MEVION S250 proton therapy system represents the latest innovation in proton therapy, providing the same precise, non-invasive treatment advantages and capabilities of larger proton therapy systems but with a significantly reduced footprint, improved reliability, high patient throughput, more advanced clinical systems, and lower implementation and operational costs. Powered by a patented gantry-mounted TriNiobium Core accelerator, the MEVION S250 has a footprint only slightly larger than a conventional linear accelerator.
In addition to the construction at First Coast Oncology, the MEVION S250 is installed at Washington University, St. Louis, MO and is under installation at Robert Wood Johnson University Hospital, New Brunswick, NJ and Oklahoma University. An additional site in Florida, MD Anderson Cancer Center in Orlando just broke ground in September 2012.
Mevion has become a leading worldwide provider of proton therapy with more than dozen MEVION S250 proton therapy systems slated to be installed in the United States including five NCI Designated Comprehensive Cancer Center, and six international projects. "The simple and modular design of the MEVION S250 supports a lean and fast manufacturing process. This is a first in proton therapy which traditionally has been limited by the enormous size and complexity of the device", says Joseph K. Jachinowski, Chief Executive Officer of Mevion Medical Systems. The MEVION S250 is the only proton therapy system designed and manufactured in the United States, and has recently received United States Food and Drug Administration 510(k) clearance and CE Certification enabling Mevion customers to treat patients.
About Mevion Medical Systems
Mevion Medical Systems, Inc. is a radiation therapy company dedicated to advancing the treatment of cancer. As the pioneering developer of proton therapy systems, Mevion provides innovative, safe and effective solutions by transforming advances in medical technology and science into practical clinical reality.
Mevion's flagship product, the MEVION S250 Proton Therapy System, is designed to preserve all of the treatment benefits of traditional proton therapy systems while removing the obstacles of size, cost, and complexity. Realizing this vision, Mevion has forever changed the economics and accessibility of proton therapy worldwide.
Founded in 2004, Mevion is a privately held company headquartered in the Boston metropolitan area with international offices in the United Kingdom and Japan.
Visit us at www.mevion.com
Mevion Medical Systems
Melanie M. Miller, 978-540-1551
Marketing Project Manager
KEYWORDS: United States North America Massachusetts
The article Mevion Medical Systems Continues Manufacturing Ramp up for its Revolutionary MEVION S250 Proton Therapy System originally appeared on Fool.com.Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.